CRISPR Expands From One Approval Into a Full Clinical Pipeline in 2026
CRISPR gene editing enters mainstream medicine as Casgevy approval fuels a clinical trial pipeline for cancer, rare diseases, and autoimmune conditions with FDA cutting red tape.
Follow the subjects shaping intelligence, science, culture, and the future of technology.
Find a subject, then follow its latest reporting and ideas.
Stories, interviews, and analysis in this subject.